Azapropazone - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Carriers (1)

Identification

Name

Azapropazone

Accession Number

DB07402

Type

Small Molecule

Groups

Withdrawn

Description

Not Available

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Azapropazone

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Rheumox	Amdipharm Mercury Company Limited

Brand mixtures

Not Available

Categories

UNII

K2VOT966ZI

CAS number

13539-59-8

Weight

Average: 298.3397
Monoisotopic: 298.14297584

Chemical Formula

C₁₆H₁₈N₄O₂

InChI Key

WOIIIUDZSOLAIW-NSHDSACASA-N

InChI

InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1

IUPAC Name

(4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0²,⁶]trideca-1(13),7,9,11-tetraene-3,5-dione

SMILES

[H][[email protected]@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Azapropazone is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Azapropazone is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Azapropazone may increase the anticoagulant activities of Abciximab.	Approved
Acebutolol	Azapropazone may decrease the antihypertensive activities of Acebutolol.	Approved
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Azapropazone.	Approved
Acenocoumarol	Azapropazone may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Azapropazone.	Approved, Vet Approved
Aclarubicin	Azapropazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.	Investigational
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Azapropazone.	Approved
Alclometasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Aldosterone.	Experimental
Alendronic acid	The risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.	Approved
Aliskiren	Azapropazone may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alprenolol	Azapropazone may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Azapropazone.	Approved, Investigational
Amcinonide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Amcinonide.	Approved
Amikacin	Azapropazone may decrease the excretion rate of Amikacin which could result in a higher serum level.	Approved, Vet Approved
Amiloride	Azapropazone may decrease the antihypertensive activities of Amiloride.	Approved
Amrubicin	Azapropazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.	Approved, Investigational
Ancrod	Azapropazone may increase the anticoagulant activities of Ancrod.	Investigational
Andrographolide	The risk or severity of adverse effects can be increased when HMPL-004 is combined with Azapropazone.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Azapropazone is combined with 4-Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Azapropazone is combined with Anecortave.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Azapropazone is combined with Anisodamine.	Investigational
annamycin	Azapropazone may decrease the excretion rate of annamycin which could result in a higher serum level.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Azapropazone.	Approved
Antithrombin III human	Azapropazone may increase the anticoagulant activities of Antithrombin III human.	Approved
Apixaban	Azapropazone may increase the anticoagulant activities of Apixaban.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Acetovanillone.	Investigational
Apramycin	Azapropazone may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Azapropazone.	Approved, Investigational
Arbekacin	Azapropazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved
Ardeparin	Azapropazone may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Argatroban	Azapropazone may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Azapropazone may decrease the antihypertensive activities of Arotinolol.	Approved
Atenolol	Azapropazone may decrease the antihypertensive activities of Atenolol.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azapropazone.	Approved
Balsalazide	Azapropazone may increase the nephrotoxic activities of Balsalazide.	Approved, Investigational
Becaplermin	Azapropazone may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Beclomethasone dipropionate.	Approved, Investigational
Befunolol	Azapropazone may decrease the antihypertensive activities of Befunolol.	Experimental
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Azapropazone.	Approved, Investigational
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azapropazone.	Approved
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Azapropazone.	Withdrawn
Beraprost	The therapeutic efficacy of Beraprost can be decreased when used in combination with Azapropazone.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Azapropazone may decrease the antihypertensive activities of Betaxolol.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Azapropazone is combined with Betulinic Acid.	Investigational
Bevantolol	Azapropazone may decrease the antihypertensive activities of Bevantolol.	Approved
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azapropazone.	Approved, Investigational
Bisoprolol	Azapropazone may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Azapropazone may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Azapropazone may decrease the antihypertensive activities of Bopindolol.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Azapropazone.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Azapropazone is combined with Bucillamine.	Investigational
Bucindolol	Azapropazone may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Budesonide.	Approved
Bufuralol	Azapropazone may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumetanide	Azapropazone may decrease the diuretic activities of Bumetanide.	Approved
Bupranolol	Azapropazone may decrease the antihypertensive activities of Bupranolol.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Candoxatril is combined with Azapropazone.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Captopril is combined with Azapropazone.	Approved
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azapropazone.	Approved
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Azapropazone.	Approved, Vet Approved, Withdrawn
Carteolol	Azapropazone may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Azapropazone may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Azapropazone.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Azapropazone is combined with Celecoxib.	Approved, Investigational
Celiprolol	Azapropazone may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Certoparin	Azapropazone may increase the anticoagulant activities of Certoparin.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Azapropazone.	Approved, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.	Approved, Vet Approved
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azapropazone.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Azapropazone.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Cilazapril is combined with Azapropazone.	Approved
Cinoxacin	Azapropazone may increase the neuroexcitatory activities of Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	Azapropazone may increase the neuroexcitatory activities of Ciprofloxacin.	Approved, Investigational
Citric Acid	Azapropazone may increase the anticoagulant activities of Citric Acid.	Nutraceutical, Vet Approved
Clobetasol	The risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol.	Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol propionate.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Azapropazone is combined with Clodronate.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Clonixin.	Approved
Cloprostenol	The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azapropazone.	Vet Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Cortisone acetate.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Curcumin.	Investigational
Cyclosporine	Azapropazone may increase the nephrotoxic activities of Cyclosporine.	Approved, Investigational, Vet Approved
D-Limonene	The risk or severity of adverse effects can be increased when Azapropazone is combined with D-Limonene.	Investigational
Dabigatran etexilate	Azapropazone may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dalteparin	Azapropazone may increase the anticoagulant activities of Dalteparin.	Approved
Danaparoid	Azapropazone may increase the anticoagulant activities of Danaparoid.	Approved, Withdrawn
Darexaban	Azapropazone may increase the anticoagulant activities of Ym150.	Investigational
Daunorubicin	Azapropazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Azapropazone is combined with Deferasirox.	Approved, Investigational
Desirudin	Azapropazone may increase the anticoagulant activities of Desirudin.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.	Approved
Desoximetasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Desoximetasone.	Approved
Desoxycorticosterone acetate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone acetate.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone isonicotinate.	Vet Approved
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azapropazone.	Approved
Dextran	Azapropazone may increase the anticoagulant activities of Dextran.	Approved, Vet Approved
Dextran 40	Azapropazone may increase the anticoagulant activities of Dextran 40.	Approved
Dextran 70	Azapropazone may increase the anticoagulant activities of Dextran 70.	Approved
Dextran 75	Azapropazone may increase the anticoagulant activities of Dextran 75.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Azapropazone.	Approved, Vet Approved
Dicoumarol	Azapropazone may increase the anticoagulant activities of Dicoumarol.	Approved
Diflorasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Diflorasone.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Azapropazone.	Approved
Difluocortolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Difluocortolone.	Approved
Difluprednate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Difluprednate.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Azapropazone.	Approved
Dihydrostreptomycin	Azapropazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.	Vet Approved
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Azapropazone.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azapropazone.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azapropazone.	Approved
Doxorubicin	Azapropazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.	Approved, Investigational
Drospirenone	Azapropazone may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Azapropazone is combined with Droxicam.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Azapropazone is combined with Duvelisib.	Investigational
E-6201	The risk or severity of adverse effects can be increased when Azapropazone is combined with E6201.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Azapropazone is combined with Ebselen.	Investigational
Edetic Acid	Azapropazone may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Azapropazone may increase the anticoagulant activities of Edoxaban.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Azapropazone.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Enalaprilat is combined with Azapropazone.	Approved
Enoxacin	Azapropazone may increase the neuroexcitatory activities of Enoxacin.	Approved
Enoxaparin	Azapropazone may increase the anticoagulant activities of Enoxaparin.	Approved
Epirizole	The risk or severity of adverse effects can be increased when Azapropazone is combined with Epirizole.	Approved
Epirubicin	Azapropazone may decrease the excretion rate of Epirubicin which could result in a higher serum level.	Approved
Eplerenone	Azapropazone may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone.	Approved
Equilenin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Equilin.	Approved
Esmolol	Azapropazone may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone sulfate.	Approved
Etacrynic acid	Azapropazone may decrease the diuretic activities of Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Azapropazone.	Approved, Investigational
Ethyl biscoumacetate	Azapropazone may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Azapropazone is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Azapropazone is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Etofenamate.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Azapropazone is combined with Etoricoxib.	Approved, Investigational
Evening primrose oil	The risk or severity of adverse effects can be increased when Azapropazone is combined with Evening primrose oil.	Approved
exisulind	The risk or severity of adverse effects can be increased when exisulind is combined with Azapropazone.	Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fenbufen.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Azapropazone.	Approved
Fenprostalene	The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Azapropazone.	Vet Approved
Fleroxacin	Azapropazone may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Azapropazone.	Approved, Withdrawn
fluasterone	The risk or severity of adverse effects can be increased when Azapropazone is combined with fluasterone.	Investigational
Fludrocortisone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fludrocortisone.	Approved
Fluindione	Azapropazone may increase the anticoagulant activities of Fluindione.	Investigational
Flumequine	Azapropazone may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Flunisolide.	Approved, Investigational
Flunixin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Flunixin.	Vet Approved
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluorometholone.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednidene.	Approved, Withdrawn
Fluprednisolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednisolone.	Approved
Fluprostenol	The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Azapropazone.	Vet Approved
Flurandrenolide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Flurandrenolide.	Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azapropazone.	Approved, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone Propionate.	Approved
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Azapropazone.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Azapropazone may increase the anticoagulant activities of Fondaparinux.	Investigational
Fondaparinux sodium	Azapropazone may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Azapropazone.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Azapropazone is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Azapropazone.	Approved
Framycetin	Azapropazone may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	Azapropazone may decrease the diuretic activities of Furosemide.	Approved, Vet Approved
Gabexate	Azapropazone may increase the anticoagulant activities of Gabexate.	Investigational
Garenoxacin	Azapropazone may increase the neuroexcitatory activities of Garenoxacin.	Investigational
Gatifloxacin	Azapropazone may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Azapropazone.	Approved, Withdrawn
Gemifloxacin	Azapropazone may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Azapropazone may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Azapropazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Azapropazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
Grepafloxacin	Azapropazone may increase the neuroexcitatory activities of Grepafloxacin.	Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Azapropazone is combined with HE3286.	Investigational
Heparin	Azapropazone may increase the anticoagulant activities of Heparin.	Approved, Investigational
Higenamine	The risk or severity of adverse effects can be increased when Azapropazone is combined with Higenamine.	Investigational
Hydralazine	Azapropazone may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone.	Approved, Vet Approved
Hydrocortisone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azapropazone.	Approved
Hygromycin B	Azapropazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.	Vet Approved
Ibandronate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.	Approved, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Azapropazone is combined with Ibuproxam.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Azapropazone.	Approved
Idarubicin	Azapropazone may decrease the excretion rate of Idarubicin which could result in a higher serum level.	Approved
Idraparinux	Azapropazone may increase the anticoagulant activities of idraparinux.	Investigational
Iloprost	The therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Imidapril is combined with Azapropazone.	Investigational
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.	Approved
Indenolol	Azapropazone may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Azapropazone is combined with Indoprofen.	Withdrawn
INNO-206	Azapropazone may decrease the excretion rate of INNO-206 which could result in a higher serum level.	Investigational
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.	Approved, Investigational
Isoxicam	The risk or severity of adverse effects can be increased when Azapropazone is combined with Isoxicam.	Withdrawn
Istaroxime	The risk or severity of adverse effects can be increased when Azapropazone is combined with Istaroxime.	Investigational
Kanamycin	Azapropazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Kebuzone.	Experimental
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Azapropazone.	Approved
Labetalol	Azapropazone may decrease the antihypertensive activities of Labetalol.	Approved
Landiolol	Azapropazone may decrease the antihypertensive activities of Aop200704.	Investigational
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Azapropazone.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Azapropazone.	Approved, Investigational
Lepirudin	Azapropazone may increase the anticoagulant activities of Lepirudin.	Approved
Levobunolol	Azapropazone may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Azapropazone may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Limaprost	The therapeutic efficacy of Limaprost can be decreased when used in combination with Azapropazone.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Azapropazone.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Azapropazone is combined with Lisofylline.	Investigational
Lithium	The serum concentration of Lithium can be increased when it is combined with Azapropazone.	Approved
Lomefloxacin	Azapropazone may increase the neuroexcitatory activities of Lomefloxacin.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Azapropazone.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Azapropazone is combined with Loxoprofen.	Approved
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azapropazone.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Azapropazone is combined with Lumiracoxib.	Approved, Investigational
Luprostiol	The therapeutic efficacy of Luprostiol can be decreased when used in combination with Azapropazone.	Vet Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azapropazone.	Approved
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Azapropazone.	Approved
ME-609	The risk or severity of adverse effects can be increased when Azapropazone is combined with ME-609.	Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone.	Approved, Vet Approved
Medrysone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azapropazone.	Approved
Melengestrol	The risk or severity of adverse effects can be increased when Azapropazone is combined with Melengestrol.	Vet Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Azapropazone.	Approved, Vet Approved
Mesalazine	Azapropazone may increase the nephrotoxic activities of Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone.	Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Azapropazone.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Methylprednisolone.	Approved, Vet Approved
Metipranolol	Azapropazone may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.	Approved
Metoprolol	Azapropazone may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Metrizamide	Azapropazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.	Approved
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Azapropazone.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Azapropazone is combined with Mizoribine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Azapropazone.	Approved
Mometasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Azapropazone.	Approved
Moxifloxacin	Azapropazone may increase the neuroexcitatory activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Nabumetone.	Approved
Nadolol	Azapropazone may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	Azapropazone may increase the anticoagulant activities of Nadroparin.	Approved
Nafamostat	Azapropazone may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Azapropazone.	Approved
Nalidixic Acid	Azapropazone may increase the neuroexcitatory activities of Nalidixic Acid.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Azapropazone.	Approved, Vet Approved
NCX 1022	The risk or severity of adverse effects can be increased when Azapropazone is combined with NCX 1022.	Investigational
Neamine	Azapropazone may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Nemonoxacin	Azapropazone may increase the neuroexcitatory activities of Nemonoxacin.	Investigational
Neomycin	Azapropazone may decrease the excretion rate of Neomycin which could result in a higher serum level.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Azapropazone.	Approved
Netilmicin	Azapropazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Azapropazone.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Nitroaspirin.	Investigational
Norfloxacin	Azapropazone may increase the neuroexcitatory activities of Norfloxacin.	Approved
Ofloxacin	Azapropazone may increase the neuroexcitatory activities of Ofloxacin.	Approved
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Oleoyl estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Azapropazone.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.	Approved
Olsalazine	Azapropazone may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Omacetaxine mepesuccinate.	Approved
Omapatrilat	The risk or severity of adverse effects can be increased when Omapatrilat is combined with Azapropazone.	Investigational
Orgotein	The risk or severity of adverse effects can be increased when Azapropazone is combined with Orgotein.	Vet Approved
Otamixaban	Azapropazone may increase the anticoagulant activities of Otamixaban.	Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Azapropazone.	Approved
Oxprenolol	Azapropazone may decrease the antihypertensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone.	Withdrawn
Pamidronate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Azapropazone is combined with Parecoxib.	Approved
Paromomycin	Azapropazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.	Approved, Investigational
Pazufloxacin	Azapropazone may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Azapropazone may increase the neuroexcitatory activities of Pefloxacin.	Approved
Penbutolol	Azapropazone may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentosan Polysulfate	Azapropazone may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Azapropazone.	Approved
Phenindione	Azapropazone may increase the anticoagulant activities of Phenindione.	Approved
Phenprocoumon	Azapropazone may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azapropazone.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone.	Approved, Investigational
Pindolol	Azapropazone may decrease the antihypertensive activities of Pindolol.	Approved
Pirarubicin	Azapropazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.	Investigational
Piretanide	Azapropazone may decrease the diuretic activities of Piretanide.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Azapropazone.	Approved, Investigational
Plicamycin	Azapropazone may decrease the excretion rate of Plicamycin which could result in a higher serum level.	Approved, Withdrawn
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Azapropazone.	Approved
Practolol	Azapropazone may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Azapropazone.	Approved
Prasterone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone.	Approved, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Azapropazone is combined with dehydroepiandrosterone sulfate.	Investigational
Prednicarbate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Prednicarbate.	Approved
Prednisolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Pregnenolone.	Experimental
Probenecid	The serum concentration of Azapropazone can be increased when it is combined with Probenecid.	Approved
Propacetamol	The risk or severity of adverse effects can be increased when Azapropazone is combined with Propacetamol.	Approved
Propranolol	Azapropazone may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Azapropazone.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Azapropazone.	Experimental
Prostalene	The therapeutic efficacy of Prostalene can be decreased when used in combination with Azapropazone.	Vet Approved
Protein C	Azapropazone may increase the anticoagulant activities of Protein C.	Approved
Protein S human	Azapropazone may increase the anticoagulant activities of Protein S human.	Approved
Protocatechualdehyde	Azapropazone may increase the anticoagulant activities of Protocatechualdehyde.	Approved
Prulifloxacin	Azapropazone may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Azapropazone.	Investigational
Puromycin	Azapropazone may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Azapropazone.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Azapropazone.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Azapropazone.	Approved
Rescinnamine	The risk or severity of adverse effects can be increased when Rescinnamine is combined with Azapropazone.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.	Experimental, Investigational
Reviparin	Azapropazone may increase the anticoagulant activities of Reviparin.	Approved
Ribostamycin	Azapropazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved
Rimexolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Azapropazone may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Azapropazone is combined with Rofecoxib.	Investigational, Withdrawn
Rosoxacin	Azapropazone may increase the neuroexcitatory activities of Rosoxacin.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Azapropazone.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Azapropazone.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Azapropazone.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone.	Experimental
Saralasin	The risk or severity of adverse effects can be increased when Saralasin is combined with Azapropazone.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Azapropazone.	Approved
Sisomicin	Azapropazone may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sotalol	Azapropazone may decrease the antihypertensive activities of Sotalol.	Approved
SP1049C	Azapropazone may decrease the excretion rate of SP1049C which could result in a higher serum level.	Investigational
Sparfloxacin	Azapropazone may increase the neuroexcitatory activities of Sparfloxacin.	Approved
Spectinomycin	Azapropazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.	Approved, Vet Approved
Spirapril	The risk or severity of adverse effects can be increased when Spirapril is combined with Azapropazone.	Approved
Spironolactone	Azapropazone may decrease the antihypertensive activities of Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Azapropazone.	Investigational
Streptomycin	Azapropazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Streptozocin	Azapropazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.	Approved
Sulfasalazine	Azapropazone may increase the nephrotoxic activities of Sulfasalazine.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Azapropazone.	Approved
Sulodexide	Azapropazone may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Azapropazone.	Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Azapropazone.	Approved, Withdrawn
Tacrolimus	Azapropazone may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Azapropazone.	Approved
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Azapropazone.	Approved
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Azapropazone.	Approved
Technetium Tc-99m etidronate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium tc 99m etidronate.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium Tc-99m Medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone.	Approved, Investigational
Temafloxacin	Azapropazone may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Temocapril is combined with Azapropazone.	Experimental, Investigational
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Azapropazone is combined with Tenofovir.	Approved, Investigational
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Azapropazone.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Azapropazone is combined with Tepoxalin.	Vet Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Azapropazone is combined with Teriflunomide.	Approved
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Azapropazone.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Azapropazone is combined with Tiludronate.	Approved, Vet Approved
Timolol	Azapropazone may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Azapropazone is combined with Tinoridine.	Investigational
Tixocortol	The risk or severity of adverse effects can be increased when Azapropazone is combined with Tixocortol.	Approved
Tobramycin	Azapropazone may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Azapropazone.	Approved
Torasemide	Azapropazone may decrease the diuretic activities of Torasemide.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Azapropazone.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Azapropazone is combined with Tranilast.	Approved, Investigational
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Azapropazone may decrease the antihypertensive activities of Triamterene.	Approved
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azapropazone.	Approved, Vet Approved
Trovafloxacin	Azapropazone may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Withdrawn
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Azapropazone.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Azapropazone is combined with Valdecoxib.	Investigational, Withdrawn
Valrubicin	Azapropazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone.	Approved, Investigational
Vancomycin	The serum concentration of Vancomycin can be increased when it is combined with Azapropazone.	Approved
Warfarin	Azapropazone may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Azapropazone may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Azapropazone.	Approved, Investigational, Withdrawn
Zoledronic acid	The risk or severity of adverse effects can be increased when Azapropazone is combined with Zoledronic acid.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone.	Withdrawn
Zorubicin	Azapropazone may decrease the excretion rate of Zorubicin which could result in a higher serum level.	Experimental

Food Interactions

Not Available

References

Synthesis Reference

Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.

General References

Not Available

External Links

Resource	Link
PubChem Compound	46937068
PubChem Substance	99443873
ChemSpider	25056860
ChEBI	38010
HET	AZQ

ATC Codes

M01AX04 — Azapropazone

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	187	Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.

Predicted Properties

Property	Value	Source
Water Solubility	0.641 mg/mL	ALOGPS
logP	0.92	ALOGPS
logP	2.08	ChemAxon
logS	-2.7	ALOGPS
pKa (Strongest Acidic)	0.52	ChemAxon
pKa (Strongest Basic)	7.58	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	56.22 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	85.69 m³·mol^-1	ChemAxon
Polarizability	31.94 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9389
Caco-2 permeable	+	0.5728
P-glycoprotein substrate	Non-substrate	0.5961
P-glycoprotein inhibitor I	Inhibitor	0.8281
P-glycoprotein inhibitor II	Inhibitor	0.6484
Renal organic cation transporter	Non-inhibitor	0.7843
CYP450 2C9 substrate	Non-substrate	0.8218
CYP450 2D6 substrate	Non-substrate	0.8107
CYP450 3A4 substrate	Substrate	0.6289
CYP450 1A2 substrate	Inhibitor	0.5528
CYP450 2C9 inhibitor	Non-inhibitor	0.8735
CYP450 2D6 inhibitor	Non-inhibitor	0.9188
CYP450 2C19 inhibitor	Non-inhibitor	0.8614
CYP450 3A4 inhibitor	Non-inhibitor	0.8273
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.725
Ames test	AMES toxic	0.5466
Carcinogenicity	Non-carcinogens	0.8321
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.4784 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7311
hERG inhibition (predictor II)	Non-inhibitor	0.8171

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Triazines

Direct Parent

Aminotriazines

Alternative Parents

Pyrazolidinones / Benzenoids / 1,3-dicarbonyl compounds / 1,2,4-triazines / Guanidines / Carboxylic acid hydrazides / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides

Substituents

Amino-1,2,4-triazine / Aminotriazine / Pyrazolidinone / 1,3-dicarbonyl compound / Benzenoid / 1,2,4-triazine / Pyrazolidine / Carboxylic acid hydrazide / Guanidine / Azacycle

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

Not Available

Carriers

Details

1. Serum albumin

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Toxic substance binding
Specific Function:: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:: ALB
Uniprot ID:: P02768
Uniprot Name:: Serum albumin
Molecular Weight:: 69365.94 Da

References

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Drug created on September 15, 2010 15:21 / Updated on September 01, 2017 11:40

Structure for DB07402 (Azapropazone)

Carriers

References